{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neulasta+%28PEG-rhG-CSF%29",
    "query": {
      "intervention": "Neulasta (PEG-rhG-CSF)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 22,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neulasta+%28PEG-rhG-CSF%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T13:33:44.496Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03220022",
      "title": "Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AIDS-Related Lymphoma",
        "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma",
        "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 46,
      "start_date": "2018-03-16",
      "completion_date": "2027-07-16",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • San Francisco, California • Miami, Florida + 12 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220022"
    },
    {
      "nct_id": "NCT00101010",
      "title": "Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "61 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "61 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2005-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 7,
      "location_summary": "Fort Smith, Arkansas • Grand Rapids, Michigan • Kalamazoo, Michigan + 4 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "East Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101010"
    },
    {
      "nct_id": "NCT06738368",
      "title": "Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative",
        "T Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Asparaginase Erwinia chrysanthemi",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-05-08",
      "completion_date": "2028-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06738368"
    },
    {
      "nct_id": "NCT04684368",
      "title": "A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Nongerminomatous Germ Cell Tumor",
        "Choriocarcinoma",
        "Embryonal Carcinoma",
        "Immature Teratoma",
        "Malignant Teratoma",
        "Mixed Germ Cell Tumor",
        "Pineal Region Germ Cell Tumor",
        "Pineal Region Immature Teratoma",
        "Pineal Region Yolk Sac Tumor",
        "Suprasellar Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Second-Look Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "3 Years to 29 Years"
      },
      "enrollment_count": 160,
      "start_date": "2021-07-13",
      "completion_date": "2029-12-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 152,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04684368"
    },
    {
      "nct_id": "NCT01933932",
      "title": "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV"
      ],
      "interventions": [
        {
          "name": "Selumetinib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pegylated G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 510,
      "start_date": "2013-09-25",
      "completion_date": "2026-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 17,
      "location_summary": "Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01933932"
    },
    {
      "nct_id": "NCT01169636",
      "title": "Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2011-01-31",
      "completion_date": "2017-05-17",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169636"
    },
    {
      "nct_id": "NCT00662519",
      "title": "Neulasta in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Neulasta (Pegylated)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mixed Meal Tolerance Test (MMTT)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Blood test",
          "type": "OTHER"
        },
        {
          "name": "DNA Test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-04",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-09",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662519"
    },
    {
      "nct_id": "NCT03907488",
      "title": "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ann Arbor Stage III Hodgkin Lymphoma",
        "Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma",
        "Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma",
        "Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma",
        "Ann Arbor Stage IV Hodgkin Lymphoma",
        "Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma",
        "Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma",
        "Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma",
        "Classic Hodgkin Lymphoma",
        "Lymphocyte-Rich Classic Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Vinblastine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 994,
      "start_date": "2019-08-29",
      "completion_date": "2027-03-28",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 711,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907488"
    },
    {
      "nct_id": "NCT00671658",
      "title": "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide (CTX)",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Pegylated asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Solumedrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 220,
      "start_date": "2002-11",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2020-12-03",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00671658"
    },
    {
      "nct_id": "NCT04628767",
      "title": "Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Renal Pelvis and Ureter Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Vinblastine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2021-11-12",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-26T13:33:44.496Z",
      "location_count": 257,
      "location_summary": "Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more",
      "locations": [
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04628767"
    }
  ]
}